nach oben

Current Rheumatology Reports

Erschienen in:

01.06.2011

Bone Health Issues in Sarcoidosis

verfasst von: Nadera J. Sweiss, Elyse E. Lower, Peter Korsten, Timothy B. Niewold, Murray J. Favus, Robert P. Baughman

Erschienen in: Current Rheumatology Reports | Ausgabe 3/2011

Einloggen, um Zugang zu erhalten

Abstract

Sarcoidosis affects the bone directly in only a minority of patients. Nonetheless, bone health should be considered in the management of all patients with sarcoidosis. Deficiency in vitamin D, an important contributor to bone health, has been linked to autoimmune disease incidence. Studies have shown that patients with sarcoidosis frequently have low levels of vitamin D-25 but may have normal or increased levels of vitamin D-1,25. In addition, granuloma formation has been linked to a failure of the innate immune system, which could be related to a deficiency in vitamin D, although this relationship has not been fully characterized. Furthermore, many patients with sarcoidosis are treated with corticosteroids, which are known to induce osteoporosis. Therefore, bone health may be impacted in several ways in sarcoidosis—by direct involvement with granulomas, vitamin D deficiency, or corticosteroid therapy.

Wilcox A, Bharadwaj P, Sharma OP. Bone sarcoidosis. Curr Opin Rheumatol. 2000;12:321–30.PubMedCrossRef

Rizzato G. Clinical impact of bone and calcium metabolism changes in sarcoidosis. Thorax. 1998;53:425–9.PubMedCrossRef

• Burke RR, Rybicki BA, Rao DS. Calcium and vitamin D in sarcoidosis: how to assess and manage. Semin Respir Crit Care Med. 2010;31:474–84. This is a great review about the nuances of managing calcium and vitamin D levels in sarcoidosis. Because it specifically focuses on sarcoidosis, it may serve as a roadmap to the supportive care that is required by these patients.PubMedCrossRef

• Richmond BW, Drake WP. Vitamin D, innate immunity, and sarcoidosis granulomatous inflammation: insights from mycobacterial research. Curr Opin Pulm Med. 2010;16:461–4. This intriguing and potentially controversial study has raised the question of whether vitamin D supplementation may not be helpful in treating sarcoidosis.PubMedCrossRef

Chatham W. Rheumatic manifestations of systemic disease: sarcoidosis. Curr Opin Rheumatol. 2010;22:85–90.PubMedCrossRef

Ugwonali OF, Parisien M, Nickerson KG, Scully B, Ristic S, et al. Osseous sarcoidosis of the hand: pathologic analysis and review of the literature. J Hand Surg Am. 2005;30:854–8.PubMedCrossRef

Shorr AF, Murphy FT, Kelly WF, Kaplan KJ, Gilliland WR, et al. Osseous Sarcoidosis Clinical, Radiographic, and Therapeutic Observations. J Clin Rheumatol. 1998;4:186–92.PubMedCrossRef

Ly JQ. An unusual cause of knee pain: a rare case of osseous sarcoid (2003:5b). Eur Radiol. 2003;13:2055–7.PubMedCrossRef

Rua-Figueroa I, Gantes MA, Erausquin C, Mhaidli H, Montesdeoca A. Vertebral sarcoidosis: clinical and imaging findings. Semin Arthritis Rheum. 2002;31:346–52.PubMedCrossRef

10.

Poyanli A, Poyanli O, Sencer S, Akan K, Sayrak H, et al. Vertebral sarcoidosis: imaging findings. Eur Radiol. 2000;10:92–4.PubMedCrossRef

11.

Binicier O, Sari I, Sen G, Onen F, Akkoc N, et al. Axial sarcoidosis mimicking radiographic sacroiliitis. Rheumatol Int. 2009;29:343–5.PubMedCrossRef

12.

Lisle D, Mitchell K, Crouch M, Windsor M. Sarcoidosis of the thoracic and lumbar spine: imaging findings with an emphasis on magnetic resonance imaging. Australas Radiol. 2004;48:404–7.PubMedCrossRef

13.

Mangino D, Stover DE. Sarcoidosis presenting as metastatic bony disease. A case report and review of the literature on vertebral body sarcoidosis. Respiration. 2004;71:292–4.PubMedCrossRef

14.

Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357:266–81.PubMedCrossRef

15.

Stechschulte SA, Kirsner RS, Federman DG. Vitamin D: bone and beyond, rationale and recommendations for supplementation. Am J Med. 2009;122:793–802.PubMedCrossRef

16.

Sharma OP. Vitamin D, calcium, and sarcoidosis. Chest. 1996;109:535–9.PubMedCrossRef

17.

Sharma OP. Vitamin D and sarcoidosis. Curr Opin Pulm Med. 2010;16:487–8.PubMedCrossRef

18.

Nam HS, Shin MH, Zmuda JM, Leung PC, Barrett-Connor E, et al. Race/ethnic differences in bone mineral densities in older men. Osteoporos Int. 2010;21:2115–23.PubMedCrossRef

19.

Mason RS, Frankel T, Chan YL, Lissner D, Posen S. Vitamin D conversion by sarcoid lymph node homogenate. Ann Intern Med. 1984;100:59–61.PubMed

20.

Adams JS, Diz MM, Sharma OP. Effective reduction in the serum 1, 25-dihydroxyvitamin D and calcium concentration in sarcoidosis-associated hypercalcemia with short-course chloroquine therapy. Ann Intern Med. 1989;111:437–8.PubMed

21.

Hamada K, Nagai S, Tsutsumi T, Izumi T. Ionized calcium and 1, 25-dihydroxyvitamin D concentration in serum of patients with sarcoidosis. Eur Respir J. 1998;11:1015–20.PubMedCrossRef

22.

• Kavathia D, Buckley JD, Rao D, Rybicki B, Burke R. Elevated 1, 25-dihydroxyvitamin D levels are associated with protracted treatment in sarcoidosis. Respir Med. 2010;104:564–70. This study has defined a relationship between elevated Vit D-1,25 and chronic sarcoidosis, thus adding further evidence of the role of vitamin D in this autoimmune disorder.PubMedCrossRef

23.

Ben-Zvi I, Aranow C, Mackay M, Stanevsky A, Kamen DL, et al. The impact of vitamin D on dendritic cell function in patients with systemic lupus erythematosus. PLoS ONE. 2010;5:e9193.PubMedCrossRef

24.

Niewold TB, Hua J, Lehman TJ, Harley JB, Crow MK. High serum IFN-alpha activity is a heritable risk factor for systemic lupus erythematosus. Genes Immun. 2007;8:492–502.PubMedCrossRef

25.

Niewold TB, Clark DN, Salloum R, Poole BD. Interferon alpha in systemic lupus erythematosus. J Biomed Biotechnol. 2010;2010:948364.PubMedCrossRef

26.

Kariuki SN, Franek BS, Kumar AA, Arrington J, Mikolaitis RA, et al. Trait-stratified genome-wide association study identifies novel and diverse genetic associations with serologic and cytokine phenotypes in systemic lupus erythematosus. Arthritis Res Ther. 2010;12:R151.PubMedCrossRef

27.

Reichel H, Koeffler HP, Tobler A, Norman AW. 1 alpha, 25-Dihydroxyvitamin D3 inhibits gamma-interferon synthesis by normal human peripheral blood lymphocytes. Proc Natl Acad Sci USA. 1987;84:3385–9.PubMedCrossRef

28.

Stoffels K, Overbergh L, Giulietti A, Verlinden L, Bouillon R, et al. Immune regulation of 25-hydroxyvitamin-D3-1alpha-hydroxylase in human monocytes. J Bone Miner Res. 2006;21:37–47.PubMedCrossRef

29.

Liu PT, Stenger S, Li H, Wenzel L, Tan BH, et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science. 2006;311:1770–3.PubMedCrossRef

30.

Swaisgood CM, Oswald-Richter K, Moeller SD, Klemenc JM, Ruple LM, et al. Development of a sarcoidosis murine lung granuloma model using mycobacterium sodA. Am J Respir Cell Mol Biol. 2010;26:26.

31.

Grossman JM, Gordon R, Ranganath VK, Deal C, Caplan L, et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res Hoboken. 2010;62:1515–26.PubMedCrossRef

32.

Montemurro L, Fraioli P, Riboldi A, Delpiano S, Zanni D, et al. Bone loss in prednisone treated sarcoidosis: a two-year follow-up. Ann Ital Med Int. 1990;5:164–8.PubMed

33.

Rizzato G, Tosi G, Mella C, Montemurro L, Zanni D, et al. Prednisone-induced bone loss in sarcoidosis: a risk especially frequent in postmenopausal women. Sarcoidosis. 1988;5:93–8.PubMed

34.

Sweiss NJ, Patterson K, Sawaqed R, Jabbar U, Korsten P, et al. Rheumatologic manifestations of sarcoidosis. Semin Respir Crit Care Med. 2010;31:463–73.PubMedCrossRef

35.

• Guiducci C, Gong M, Xu Z, Gill M, Chaussabel D, et al. TLR recognition of self nucleic acids hampers glucocorticoid activity in lupus. Nature. 2010;465:937–41. This thought-provoking and somewhat controversial report has provided a potential explanation for the differential efficacy of corticosteroids in treatment of SLE.PubMedCrossRef

36.

Baughman RP, Drent M, Kavuru M, Judson MA, Costabel U, et al. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med. 2006;174:795–802.PubMedCrossRef

37.

Callejas-Rubio JL, Ortego-Centeno N, Lopez-Perez L, Benticuaga MN. Treatment of therapy-resistant sarcoidosis with adalimumab. Clin Rheumatol. 2006;25:596–7.PubMedCrossRef

38.

Sweiss NJ, Barnathan ES, Lo K, Judson MA, Baughman R. C-reactive protein predicts response to infliximab in patients with chronic sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2010;27:49–56.PubMed

39.

Garg S, Garg K, Altaf M, Magaldi JA. Refractory vertebral sarcoidosis responding to infliximab. J Clin Rheumatol. 2008;14:238–40.PubMedCrossRef

40.

Agrawal S, Bhagat S, Dasgupta B. Sarcoid sacroiliitis: successful treatment with infliximab. Ann Rheum Dis. 2009;68:283.PubMedCrossRef

41.

Moravan M, Segal BM. Treatment of CNS sarcoidosis with infliximab and mycophenolate mofetil. Neurology. 2009;72:337–40.PubMedCrossRef

42.

Rossman MD, Newman LS, Baughman RP, Teirstein A, Weinberger SE, et al. A double-blinded, randomized, placebo-controlled trial of infliximab in subjects with active pulmonary sarcoidosis. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Sarcoidosis Vasc Diffuse Lung Dis. 2006;23:201–8.PubMed

43.

Ulbricht KU, Stoll M, Bierwirth J, Witte T, Schmidt RE. Successful tumor necrosis factor alpha blockade treatment in therapy-resistant sarcoidosis. Arthritis Rheum. 2003;48:3542–3.PubMedCrossRef

44.

Sweiss NJ, Noth IN, Baughman RP, Curran J, Naureckas E, et al. 52-Week Trial Results of Adalimumab as Novel Therapy for Refractory, Progressive Pulmonary Sarcoidosis. American Thoracic Society 2010 International Conference; New Orleans, LA Abstract A2370. 2010.

45.

Menon Y, Cucurull E, Reisin E, Espinoza LR. Interferon-alpha-associated sarcoidosis responsive to infliximab therapy. Am J Med Sci. 2004;328:173–5.PubMedCrossRef

46.

Ishibashi K, Kodama M, Hanada S, Arima T. Tumor necrosis factor-beta and hypercalcemia. Leuk Lymphoma. 1992;7:409–17.PubMedCrossRef

47.

Mundy GR. Incidence and pathophysiology of hypercalcemia. Calcif Tissue Int. 1990;46(Suppl):S3–10.PubMedCrossRef

48.

Bachwich PR, Lynch 3rd JP, Larrick J, Spengler M, Kunkel SL. Tumor necrosis factor production by human sarcoid alveolar macrophages. Am J Pathol. 1986;125:421–5.PubMed

49.

Adams JS, Sharma OP, Diz MM, Endres DB. Ketoconazole decreases the serum 1, 25-dihydroxyvitamin D and calcium concentration in sarcoidosis-associated hypercalcemia. J Clin Endocrinol Metab. 1990;70:1090–5.PubMedCrossRef

50.

Rizzato G, Colombo P. Nephrolithiasis as a presenting feature of chronic sarcoidosis: a prospective study. Sarcoidosis Vasc Diffuse Lung Dis. 1996;13:167–72.PubMed

51.

Dawson-Hughes B. A revised clinician's guide to the prevention and treatment of osteoporosis. J Clin Endocrinol Metab. 2008;93:2463–5.PubMedCrossRef

52.

Teitelbaum SL, Seton MP, Saag KG. Should bisphosphonates be used for long-term treatment of glucocorticoid-induced osteoporosis? Arthritis Rheum. 2010;8:8.

53.

Arai T, Inoue Y, Hayashi S, Yamamoto S, Sakatani M. Risedronate induced BOOP complicated with sarcoidosis. Thorax. 2005;60:613–4.PubMedCrossRef

54.

Rolla G, Bucca C, Brussino L. Bisphosphonate-induced bronchoconstriction in aspirin-sensitive asthma. Lancet. 1994;343:426–7.PubMedCrossRef

55.

Pena de la Vega L, Fervenza FC, Lager D, Habermann T, Leung N. Acute granulomatous interstitial nephritis secondary to bisphosphonate alendronate sodium. Ren Fail. 2005;27:485–9.PubMedCrossRef

56.

Buysschaert M, Cosyns JP, Barreto L, Jadoul M. Pamidronate-induced tubulointerstitial nephritis with Fanconi syndrome in a patient with primary hyperparathyroidism. Nephrol Dial Transplant. 2003;18:826–9.PubMedCrossRef

57.

Smetana S, Michlin A, Rosenman E, Biro A, Boaz M, et al. Pamidronate-induced nephrotoxic tubular necrosis—a case report. Clin Nephrol. 2004;61:63–7.PubMed

58.

Thiebaud D, Sauty A, Burckhardt P, Leuenberger P, Sitzler L, et al. An in vitro and in vivo study of cytokines in the acute-phase response associated with bisphosphonates. Calcif Tissue Int. 1997;61:386–92.PubMedCrossRef

Titel: Bone Health Issues in Sarcoidosis
verfasst von: Nadera J. Sweiss
Elyse E. Lower
Peter Korsten
Timothy B. Niewold
Murray J. Favus
Robert P. Baughman
Publikationsdatum: 01.06.2011
Verlag: Current Science Inc.
Erschienen in: Current Rheumatology Reports / Ausgabe 3/2011
Print ISSN: 1523-3774
Elektronische ISSN: 1534-6307
DOI: https://doi.org/10.1007/s11926-011-0170-1

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2011

Antisynthetase Syndrome

The Muscular Dystrophies: Distinct Pathogenic Mechanisms Invite Novel Therapeutic Approaches

Therapeutic Approaches in Myositis

New Imaging Modalities in Bone

Advances in Glucocorticoid-Induced Osteoporosis